anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The pathogenic outcome of enteric virus infections is governed by a complex interplay between the virus, intestinal microbiota, and host immune factors, with metabolites serving as a key mediator. Noroviruses bind bile acid metabolites, which are produced by the host and then modified by commensal bacteria. Paradoxically, bile acids can have both proviral and antiviral roles during norovirus infections. Working in an infant mouse model of norovirus infection, we demonstrate that microbiota and their bile acid metabolites protect from norovirus diarrhea, whereas host bile acids promote disease. We also find that maternal bile acid metabolism determines the susceptibility of newborn mice to norovirus diarrhea during breastfeeding. Finally, targeting maternal and neonatal bile acid metabolism can protect newborn mice from norovirus disease. In summary, neonatal metabolic immaturity and breastmilk bile acids are central determinants of heightened newborn vulnerability to norovirus disease.
In a 24 week randomized controlled trial based in a large urban area with high rates of opioid use disorder (OUD) and HIV, 250 out-of-treatment opioid users who utilize syringe exchanges will be recruited and randomize to receive an onsite treatment intervention (O-BMT) or enhanced referral to buprenorphine treatment. Over 2 weeks, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment. In the control arm, participants will receive enhanced referral to the community health center for maintenance buprenorphine treatment. Data collection will include urine drug tests, questionnaires, and medical and pharmacy record review. Key outcomes will include engagement in buprenorphine treatment, treatment outcomes, and programmatic costs. Buprenorphine diversion will be assessed by using electronic monitors that estimate medication adherence, testing urine samples for buprenorphine, and through sequential surveys regarding buying or selling illicit buprenorphine.
PURPOSE: A combination kit containing pinitol and a drug for preventing or treating diabetes is provided to reduce side effects and to quickly treat diabetes. CONSTITUTION: A combination kit of a component for preventing or treating diabetes contains pinitol as a first ingredient, and a drug of biguanide, meglitinide, or sulfonylurea as a second ingredient. The biguanide is metformin. The meglitinide is repaplinide or nateglinide. The sulfonylurea is carbutamide, acetohexamide, chlorpropamide, tolbutamide, tolazamide, gliclazide, glibenclamide, gliquidone, glyclopyramide, or glimepiride. [Reference numerals] (AA) Insulin; (BB) Control group; (CC) Before injection; (DD) 3 days after injection; (EE) 2 weeks after injection; (FF) 4 weeks after injection; (GG) 8 weeks after injection
The overall aim of this study is to examine the effects of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) on chronic pain symptoms, specifically we will examine the effects of different doses of THC/CBD on symptoms of chronic pain and life functioning. Participants will include individuals with chronic pain, who will be randomized into one of three intervention conditions: high THC/low CBD, low THC/high CBD, or placebo. In addition to receiving THC/CBD/placebo, participants also will complete symptom assessments of chronic pain data (intensity, quality, interference/disability) throughout the study. These measures will be gathered prior to and following the fifth doses (dosing will occur once per day for five days) of CBD/THC or placebo. A secondary objective will be to examine the association between clinical and neurocognitive variables and use of CBD/THC, including the potential side effects of THC/CBD. Other secondary objectives include the use of magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), acquired before and after final administration with CBD/THC or placebo to examine differences in brain metabolism, brain connectivity, and brain structure. Imaging analyses will focus on regional brain changes before and after administration of THC/CBD/placebo.
Non-small cell lung cancer (NSCLC) is characterized by a high incidence rate and poor prognosis worldwide. A deeper insight into the pathogenesis of NSCLC and identification of novel therapeutic targets are essential to improve the prognosis of NSCLC. In this study, we revealed that fibrinogen-like protein 1 (FGL1) promotes proliferation, migration, and invasion of NSCLC cells. Mechanistically, we found that Stat3 acts as a transcription factor and can be recruited to the FGL1 promoter, enhancing FGL1 promoter activity. Lysine-specific demethylase 4A (KDM4A) interacts with Stat3 and facilitates the removal of methyl groups from H3K9me3, thereby enhancing Stat3-mediated transcription of FGL1. Furthermore, we observed that Stat3 and KDM4A promote NSCLC cell proliferation, migration, and invasion partly by upregulating FGL1 expression. Additionally, the expression of FGL1 was significantly higher in cancer tissues (n = 90) than in adjacent non-cancerous tissues (n = 90). Furthermore, patients with high FGL1 expression had a shorter overall survival (OS) compared to those with low FGL1 expression. We measured the expression levels of FGL1 on circulating tumor cells (CTCs) in 65 patients and found that patients with a dynamic decrease in FGL1 expression on CTCs exhibited a better therapeutic response. These findings suggest that the dynamic changes in FGL1 expression can serve as a potential biomarker for predicting treatment efficacy in NSCLC. Overall, this study revealed the significant role and regulatory mechanisms of FGL1 in the development of NSCLC, suggesting its potential as a therapeutic target for patients with NSCLC. Future studies should provide more personalized and effective treatment options for patients with NSCLC to improve clinical outcomes.
PROBLEM TO BE SOLVED: To prepare a preparation capable of preventing and treating periodontosis by including a peptide or a salt thereof as an active ingredient. SOLUTION: This preparation contains a peptide of the formula or a salt thereof. The preparation further contains a nutrition component such as ascorbic acids, arginine, glutamine and vitamin A, having activities for repairing tissue. The containing amounts thereof are 0.0001-10 wt.% of the compound of the formula or the salt thereof, and 0.001-99 wt.% of the nutrition component. The peptide of the formula is obtained by culturing a strain for producing the peptide, belonging to the genus Streptomyces (e.g. Streptomyces nobilis), extracting the cultured strain with an organic solvent, and subjecting the extract to a column chromatography. The preparation has strong antimicrobial activities, antiinflammatory activities and tissue-repairing activities, and further manifests synergetic activities by using the nutrition component in combination and becomes more effective.
Disclosed is a method for providing mobile medical information. The present invention enables a doctor to confirm a medical record with a mobile terminal or explain a situation of a patient with a video or an image to the patient. When the doctor enters a specific hospital room, a mobile terminal for the doctor recognizes a mobile terminal for the patient and shares the video and the image with the mobile terminal for the patient. When the doctor in charge is absent, a fellow doctor selects an important image and shares the image with the doctor in charge. The present invention shows what the doctor in charge has successfully completed medical cases. [Reference numerals] (411) I/O ESD RC-clamp;(413) Core ESD RC-clamp;(427) Blocking circuit;(AA,BB) ESD design path from VDD1 to VDD2;(CC) VDD2(Core);(DD) VSS2(Core)
PURPOSE:To provide a stable oil-in-polyhydric-alcohol type emulsion composition, by combining an oil-insoluble polyhydric alcohol, lecithin, and, if required, a nonionic surfactant, and adding an oil-phase component. CONSTITUTION:A hydrophilic polyhydric alcohol having two or more hydroxyl gps. in the molecule, such as ethylene glycol or propylene glycol, and a lecithin such as animal lecithin or vegetable lecithin including soybean lecithin and corn lecithin are used in a ratio of the lecithin to the polyhydric alcohol of 1:0.5-1:20. The oil-phase component is an animal or vegetable oil such as beef tallow or olive oil, and a total amount of the polyhydric alcohol and lecithin is more than 10% of the oil-phase component. As required, the emulsifying property is improved by adding a nonionic surfactant such as cane sugar fatty acid ester. The process provides an oil-in-polyhydric alcohol type emulsion composition applicable in many fields such as food, cosmetics, medicine, and feed.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of hydroxyiminoalkanoic acid of the formula (I)   wherein R 1  represents oxazolyl optionally substituted with 1-2 substituents taken among lower alkyl, phenyl, thienyl, furyl; thiazolyl optionally substituted with 1-2 substituents taken among lower alkyl, phenyl; unsubstituted quinolinyl and so on; X represents a linkage or group NR 6  wherein R 6  represents hydrogen atom or C 1-4 -alkyl; n is a whole number from 1 to 3; Y represents oxygen atom or group NR 7  wherein R 7  represents hydrogen atom; ring A represents benzene ring optionally substituted with one or two C 1-4 -alkoxy-group; p is a whole number from 1 to 3; R 2  represents phenyl optionally substituted with lower alkyl, halogen atom and so on; unsubstituted furyl; unsubstituted pyridyl; pyridinyl-1-oxide; q is a whole number from 0 to 6; m represents 0 or 1; R 3  represents hydroxy-group, lower alkoxy-group or -NR 9 R 10  wherein R 9  and R 10  represent similar or different groups taken among hydrogen atom, lower alkyl and lower alkylsulfonyl; R 4  and R 5  represent similar or different groups taken among hydrogen atom or lower alkyl; or their salt. Invention relates also to pharmaceutical composition eliciting hypoglycemic and hypolipidemic effects containing compound of the formula (I) and pharmacologically acceptable carrier and to agent used for regulation of retinoid receptors containing compound of the formula (I). Invention provides preparing novel derivatives of hydroxyiminoalkanoic acid showing hypoglycemic and hypolipidemic effects. EFFECT: valuable medicinal and pharmacological properties of compounds. 21 cl, 2 dwg
This group includes frontline healthcare workers who are actively involved in the management of the Covid-19 outbreak: from emergency units, non-intensive Covid-19 and intensive Covid-19 units. They will fill self-reported questionnaires and scales upon their inclusion.
Patients receive placebo PO on days 1, 2, 8, 9, 15, and 16 and gemcitabine hydrochloride as patients in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Irritable bowel syndrome is common in children and exhibits a high placebo response. This study was to explore the placebo response rate and its influencing factors in children with irritable bowel syndrome.
METHODS: A systematic search was performed on Pubmed, Embase, MEDLINE, Cochrane Library, CNKI, Wanfang, and CBM from database inception to March 2022. Randomized controlled trials of irritable bowel syndrome in children were included in the study. The primary outcome was the placebo response rate of improvement.
RESULTS: Thirteen studies were included, with 445 patients in the placebo group. The rate of improvement and abdominal pain disappearance were 28.2% (95% CI, 16.6-39.9%) and 5% (95% CI, 0-18.4%). The placebo response based on the abdominal pain score was 0.675 (95% CI, 0.203-1.147). The mode of administration (P < 0.01), dosing schedule (P < 0.01), and clinical outcome assessor (P = 0.04) have a significant impact on the magnitude of placebo effect.
CONCLUSIONS: The placebo response rate for pediatric irritable bowel syndrome was 28.2%. In clinical trials, reducing dosing frequency, selecting appropriate dosage forms, and using patient-reported outcomes can help mitigate the placebo effect.
IMPACT: This is the first meta-analysis to assess the placebo response rates for improvement and disappearance in children with IBS. The finding suggested that the mode of administration, dosing schedule, and clinical outcome assessor could potentially influence the magnitude of the placebo effect in children with IBS. This study would provide a basis for estimating sample size in clinical trial design with a placebo control.
Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT \& infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
PROBLEM TO BE SOLVED: To more rapidly, more effectively and further inexpensively produce a therapeutic solution derived from plasma by separating albumin, etc., from unnecessary proteins and manufacturing debris by using sodium caprylate as a partitioning agent. SOLUTION: Sodium caprylate as a partitioning agent is added to a colloidal effluent material (namely, a mixed solution of vascular proteins) comprising albumin, unnecessary non-albumin protein and impurities as shown in the figure. The mixed solution is incubated after increasing temperature and pH and the colloidal solution is reacted with sodium caprylate as the partitioning agent to break the colloidal solution. Thereby, the mixed solution is divided into a supernatant liquid containing albumin and a disperse phase containing unnecessary non-albumin proteins (e.g. globulin) and manufacturing debris. Albumin is obtained from the supernatant. The albumin solution, α-1 protease inhibitor and antithrombin 111 are included in the therapeutic solution derived from plasma. The albumin product is especially suitable for intravenous injection.
Patients undergo pulmonary suffusion consisting of cisplatin via infusion. Patients the undergo metastasectomy. Beginning 4-8 weeks, patients with unresectable sarcoma may receive chemotherapy.
Methods for ablating tissue in a patient having atrial fibrillation comprise advancing an elongate flexible shaft through a patient's vasculature into a chamber of a heart. The elongate flexible shaft has an energy source and a sensor. Tissue in the heart is scanned with the sensor and data about the tissue is captured. The captured data is grouped into one of a plurality of tissue classifications and an anatomical map of the tissue showing the grouped data is displayed. At least a portion of the tissue is ablated so as to form a conduction block that blocks aberrant electrical pathways in the heart. The ablated tissue is grouped into one or more predefined tissue classifications during or prior to the ablation.
15% CLINISOL - sulfite-free (Amino Acid) Injection Pharmacy Bulk Package is a sterile, clear, nonpyrogenic, hypertonic solution of essential and nonessential amino acids. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). Exposure to temperatures above 25ºC/77ºF during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological test for plastic containers as well as by tissue culture toxicity studies.

Each 100 mL of 15% CLINISOL - sulfite-free (Amino Acid) Injection Pharmacy Bulk Package contains:
The present invention relates to efficient devices for administration of pharmaceutical agents into the skin of the human body. In particular the present invention provides devices for vaccination into the skin. The present invention provides a pharmaceutical agent delivery device having skin-piercing portion comprising a solid reservoir medium containing the pharmaceutical agent, wherein the reservoir medium is coated onto the skin piercing portion.  alternatively, the skin piercing portion may consist of the solid pharmaceutical agent reservoir medium. The pharmaceutical delivery devices are proportioned such that agent is delivered into defined layers of the skin, and preferred delivery devices comprise skin-piercing portions that deliver the pharmaceutical agent into the epithelium or the dermis. Preferred reservoir media comprise sugars, and in particular stabilising sugars that forms a glass such as lactose, raffinose, trehalose or sucrose. Furthermore, vaccine delivery devices for administration of vaccines into the skin are provided, methods of their manufacture, and their use in medicine.
PROBLEM TO BE SOLVED: To provide an intraoral-disintegrative type composition having an appropriate strength necessary for handling medicinal preparations and promptly disintegrating in oral cavities, to provide a method for producing the composition, and to provide a medicinal preparation by using the composition. SOLUTION: This intraoral-disintegrative type composition is a hardened- molded composition and promptly disintegrable in oral cavities, and contains an organic acid, a carbonate salt, a network-maintaining agent forming a network with the organic acid and the carbonate salt, and a coloring inhibitor. The network-maintaining agent is a water-insoluble solid substance such as cornstarch, and the coloring inhibitor is a water-soluble saccharide such as erythritol. The network-maintaining agent and the coloring inhibitor are compounded in amounts of 25.0-625.0 pts.wt. and 25.0-937.5 pts.wt., respectively, per 100 pts.wt. of the mixture of the organic acid and the carbonate salt.
PROBLEM TO BE SOLVED: To evade PI(polyimide) solidification even at the time of continuous PI printing by forming a PI pattern edge part, where many mesh points having higher hardness than a PI pattern part are formed around the PI pattern part corresponding to an ineffective screen of an LCD panel. SOLUTION: The PI pattern edge part is formed by being covered by making use of a shadow mask 25 obtd. by forming the opening in the part of photosensitive resin plate(ARP) unstatured resin 22 corresponding to the PI pattern and then irradiated by an ultraviolet-ray lamp 20 of about 40 W for about 1 to 2 minutes. Only the PI pattern is exposed and decreases in hardness through the primary soft exposure under these conditions. Further, irradiation is performed by the ultraviolet-ray lamp 20 for about 1 to 2 minutes after the PI pattern is covered by using the shadow mask of the size corresponding to the PI pattern part of the ARP unsatured resin 22. Only the PI pattern edge part is exposed and increases in hardness through the secondary soft exposed under these conditions.
In this population-based study, participants will undergo a low-dose chest CT scan for two rounds. At baseline, the first CT scan will be performed in all participants and their data will be collected. One-year after the baseline, a second CT scan will be performed and data will be collected again. CT images of each participant will be read twice independently by two groups of readers after the baseline and 1-year follow-up scans. In the first reading, the detected lung nodules are evaluated for diameter and managed according to a routine diameter-based protocol. The clinical management of participants are based on the first reading. In the second reading, each scan will be interpreted again by radiologists, blinded to the first reading. Semi-automated volumetry software will be used. The lung nodules will be evaluated for volume and management will be simulated according to a European volume-based protocol. Participants will be followed up and any diagnosis of lung cancer and related information will be collected at the fourth year through the hospital information system and by contacting the participants or their relatives.
FIELD: medicine. ^ SUBSTANCE: composition is applied for treatment of dry-eye syndrome. The composition for treatment of dry-eye syndrome contains omega-3 fatty acids and omega-6 fatty acids, zinc compounds, preferentially in the form of zinc sulphate. It can be applied as a dietary supplement to the balanced diet. ^ EFFECT: effective treatment of dry-eye syndrome. ^ 14 cl, 12 ex
Bloodstream infections (BSIs) are common and lethal, ranking among the top 7 causes of death, with 600,000 cases and 90,000 deaths per year in North America, and 1.2 Million cases and 150,000 deaths per year in Europe. Despite being a leading cause of death worldwide, bloodstream infections remain understudied. Treatment approaches are complicated by rising rates of antimicrobial resistance and declining new drug development.

BALANCE+ provides a platform upon which to answer multiple pressing cross-cutting questions for patients with Gram negative bloodstream infections, including the concept of de-escalating antibiotic spectrum, optimal transition to oral antibiotics, and the role for routine follow up blood culture testing. The trial will also include a syndrome-specific question of whether to remove or retain a central vascular catheter, and a pathogen-specific question of whether cephalosporins are sufficient for patients with low-risk AmpC organisms. As each question is answered, optimal therapies will be adopted into usual care, and new questions will be introduced into the platform of the trial. The evidence generated by BALANCE+ will improve cure for this vulnerable patient population.
PURPOSE:To eliminate the generation of a pressure pain, by constituting a lining material layer of a room temp. plastic material layer and a rubber elastic material layer. CONSTITUTION:A lining material layer 3 is formed to a denture base 1 having an artificial tooth 2 implanted therein on the mucous membrane surface side thereof. The lining material layer 3 consists of the room temp. plastic material layer 4 positioned on the side of the denture base 1 and the rubber elastic material layer 5 bonded to the denture base 1 at the peripheral part thereof and sealing the room temp. plastic material layer 4 between the denture base 1 and said layer 5. When occlusion force is applied to the artificial tooth 2, pressure is added to the room temp. plastic material layer 4 through the rubber elastic material layer 5 and the room temp. plastic material is deformed to press the mucous membrane surface of the alveolar ridge 7 by uniform force.